Studies showed that the combination of USP7 inhibitors with bortezomib exhibited a synergistic activity against multiple myeloma, suggesting a promising therapeutic strategy for overcoming resistance to current treatments [95]. The gene discussed is USP7; the disease is AL amyloidosis.